Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China - Thailand PR News - [Banking](https://thailandbusinessnews.net/category/banking/) - [Companies](https://thailandbusinessnews.net/category/companies/) - [Economy](https://thailandbusinessnews.net/category/economy/) - [Press Releases](https://thailandbusinessnews.net/category/press-release/) - [PR Newswire](https://thailandbusinessnews.net/pr-newswire-updates/) - [Tech](https://thailandbusinessnews.net/category/tech/) - [Tourism](https://thailandbusinessnews.net/category/tourism/) - [Press Release](https://thailandbusinessnews.net/category/press-release/) # Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China ##### Up next ![Vistra appoints Kim Jenkins as Group Chief Executive Officer](https://i0.wp.com/r2.thailandbusinessnews.net/2025/07/Kim_Jenkins___Group_CEO___Vistra.jpg?resize=200%2C110&ssl=1 "Vistra appoints Kim Jenkins as Group Chief Executive Officer") [](https://thailandbusinessnews.net/press-release/vistra-appoints-kim-jenkins-as-group-chief-executive-officer-2/) ###### [Vistra appoints Kim Jenkins as Group Chief Executive Officer](https://thailandbusinessnews.net/press-release/vistra-appoints-kim-jenkins-as-group-chief-executive-officer-2/) Published on 04 July 2025 ##### Author ##### [ CISION PRNewswire ](https://thailandbusinessnews.net/author/cision/) ##### Tags - [PRNewswire](https://thailandbusinessnews.net/tag/prnewswire/) ![](https://mma.prnasia.com/media2/1690538/Logo.jpg?p=medium600 "logo") Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater China Brii Biosciences retains ex-Greater China rights to address the global antimicrobial resistance threats and continues investment in other priority pipeline assets DURHAM, N.C. and BEIJING, July 3, 2025 /PRNewswire/ — [Brii Biosciences Limited](https://www.briibio.com/en/) ("Brii Bio," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, today announced that it has entered into a license and technology transfer agreement with Joincare Pharmaceutical Group Industry Co., Ltd ("Joincare Group"). Joincare Group will obtain an exclusive license from Brii Bio for the research, development, and commercialization of BRII-693 in the Greater China region. Under the terms of the agreement, Joincare Group will assume full responsibility for the development, regulatory approval and commercialization of BRII-693 in Greater China. In return, Brii Bio has received an upfront payment and will receive additional development and commercial milestone payments upon certain future milestone events plus tiered royalties on net product sales. BRII-693 is a novel synthetic lipopeptide in development for the treatment of critically ill patients with multidrug- and extensively drug-resistant (MDR/XDR) gram-negative bacterial infections, particularly those caused by carbapenem-resistant Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA) and Enterobacterales (CRE). [Discovered](https://www.nature.com/articles/s41467-022-29234-3#:~:text=Previously,%20we%20established%20an%20SAR-based%20mechanistic) through iterative structural modifications of the polymyxin scaffold, BRII-693 was designed to enhance antibacterial potency while reducing the toxicity commonly associated with older polymyxin agents such as renal and neuro-toxicities. [In phase 1 studies,](https://journals.asm.org/doi/10.1128/aac.01288-24) BRII-693 demonstrated a favorable safety, tolerability, and PK profile in healthy non-Chinese and Chinese participants. Brii Bio received IND approval from CDE of NMPA for a Phase 1 PK bridging study in China supporting a future Phase 3 registrational trial in patients with hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. Dr. Zhi Hong, Chairman and Chief Executive Officer of Brii Bio, commented: "The growing threat of antimicrobial resistance in Greater China underscores the urgency for novel hospital antibiotics. With Joincare Group’s proven capabilities in manufacturing and commercializing hospital antibiotics, we found the ideal partner to accelerate the development and commercialization of BRII-693. This partnership enables us to deliver a critical care medicine to Chinese patients facing life threatening infections." Mr. Nanqi Lin, Chief Executive Officer of Joincare Group, stated, "The Company has a long-standing track record of excellence in innovative drug research and development, underpinned by deep scientific expertise and a robust R&D platform. Driven by Brii Bio’s well-established R&D system, the BRII-693 project demonstrated strong innovation and scientific rigor. Early data showing encouraging results in terms of therapeutic potential, pharmacodynamics, and pharmacokinetics, suggesting BRII-693’s high potential to become a best-in-class therapy to address the critical unmet clinical needs. We are confident in the clinical prospects of BRII-693. This collaboration further strengthened Joincare Group’s strategic positioning in the anti-infection disease area. We look forward to launching this asset soon, providing patients with more high-quality treatment options." About BRII-693 BRII-693 is a novel synthetic lipopeptide in development for the treatment of critically ill patients with MDR/XDR gram-negative bacterial infections, especially carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Brii Bio holds exclusive global rights to develop and commercialize BRII-693. About Brii Bio Brii Biosciences Limited ("Brii Bio", stock code: 2137.HK) is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases, the Company is advancing a broad pipeline of unique therapeutic candidates with lead programs against hepatitis B virus (HBV) infection. The Company is led by a visionary and experienced leadership team and has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. For more information, visit [www.briibio.com](https://www.briibio.com/en/). About Joincare Group Established in 1992, Joincare Group (Joincare Pharmaceutical Group Industry Co., Ltd) is an innovative scientific research-based integrated pharmaceutical group after many years of steady operation and rapid development. The group owns two major listed companies, Joincare and Livzon Pharmaceutical, as well as more than 20 major holding subsidiaries. The company has always adhered to the concept of scientific and technological innovation as the cornerstone, implementing a dual-driver strategy focused on innovative drugs and high-barrier complex formulation technology platforms, and has carried out rich pipeline layouts around respiratory, anti-infective, gastrointestinal, assisted reproduction, psychiatric, oncology and other areas of significant clinical needs, forming a rich and diversified product matrix and pipeline of drugs under development. Forward-looking Statements This contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management’s intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance. [Source link ](https://www.prnasia.com/story/archive/4724169_AE24169_0?rand=89749) ``` This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network ``` ##### You May Also Like [](https://thailandbusinessnews.net/press-release/cstone-announces-fda-clearance-of-ind-application-for-its-novel-trispecific-antibody-cs2009-pd-1-vegf-ctla-4-to-advance-into-phase-ii-clinical-trial/) ## CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - February 16, 2026 [](https://thailandbusinessnews.net/press-release/u-s-institute-of-peace-announces-visaka-dharmadasa-the-fifth-annual-women-building-peace-award-laureate/) ## U.S. Institute of Peace Announces Visaka Dharmadasa the Fifth Annual Women Building Peace Award Laureate WASHINGTON, Feb. 27, 2025 /PRNewswire/ — The U.S. Institute of Peace (USIP)… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - February 27, 2025 [](https://thailandbusinessnews.net/press-release/payjoy-powers-progress-smartphone-finance-unlocks-credit-access-for-13-million/) ## PayJoy Powers Progress: Smartphone Finance Unlocks Credit Access for 13 Million Ethical lending ensures greater financial stability for millions of underserved around the… - [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire") - December 12, 2024 ##### Most Read - [![Priority Pass to accelerate travel innovation, backed by the Collinson Group's £500 million growth programme](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/priority-pass-to-accelerate-travel-innovation-backed-by-the-collinson-groups-500-million-growth-programme-2/ "Priority Pass to accelerate travel innovation, backed by the Collinson Group's £500 million growth programme") [Priority Pass to accelerate travel innovation, backed by the Collinson Group's £500 million growth programme](https://thailandbusinessnews.net/press-release/priority-pass-to-accelerate-travel-innovation-backed-by-the-collinson-groups-500-million-growth-programme-2/ "Priority Pass to accelerate travel innovation, backed by the Collinson Group's £500 million growth programme") - [![Modern Meadow and Bellroy Partner on Carry Products Made of Next-Generation Material](https://i0.wp.com/r2.thailandbusinessnews.net/2025/04/MODERN_MEADOW_LOGO_BLACK_PNG_Logo.jpg?fit=597%2C138&ssl=1&resize=40%2C40)](https://thailandbusinessnews.net/press-release/modern-meadow-and-bellroy-partner-on-carry-products-made-of-next-generation-material/ "Modern Meadow and Bellroy Partner on Carry Products Made of Next-Generation Material") [Modern Meadow and Bellroy Partner on Carry Products Made of Next-Generation Material](https://thailandbusinessnews.net/press-release/modern-meadow-and-bellroy-partner-on-carry-products-made-of-next-generation-material/ "Modern Meadow and Bellroy Partner on Carry Products Made of Next-Generation Material") - [![IMG Completes Acquisition of World Nomads, Expanding Global Travel Insurance Distribution](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/img-completes-acquisition-of-world-nomads-expanding-global-travel-insurance-distribution/ "IMG Completes Acquisition of World Nomads, Expanding Global Travel Insurance Distribution") [IMG Completes Acquisition of World Nomads, Expanding Global Travel Insurance Distribution](https://thailandbusinessnews.net/press-release/img-completes-acquisition-of-world-nomads-expanding-global-travel-insurance-distribution/ "IMG Completes Acquisition of World Nomads, Expanding Global Travel Insurance Distribution") - [![DORCO Wins 2026 Red Dot Award for Renewed Corporate Identity](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/dorco-wins-2026-red-dot-award-for-renewed-corporate-identity/ "DORCO Wins 2026 Red Dot Award for Renewed Corporate Identity") [DORCO Wins 2026 Red Dot Award for Renewed Corporate Identity](https://thailandbusinessnews.net/press-release/dorco-wins-2026-red-dot-award-for-renewed-corporate-identity/ "DORCO Wins 2026 Red Dot Award for Renewed Corporate Identity") - [![Tamarind Health launches Rare Cancer Centre to make specialist expertise easier to access](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/tamarind-health-launches-rare-cancer-centre-to-make-specialist-expertise-easier-to-access/ "Tamarind Health launches Rare Cancer Centre to make specialist expertise easier to access") [Tamarind Health launches Rare Cancer Centre to make specialist expertise easier to access](https://thailandbusinessnews.net/press-release/tamarind-health-launches-rare-cancer-centre-to-make-specialist-expertise-easier-to-access/ "Tamarind Health launches Rare Cancer Centre to make specialist expertise easier to access") - [![MemoMind One Rolls Out New Features and Prepares for a New Stage of Developer Access](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/memomind-one-rolls-out-new-features-and-prepares-for-a-new-stage-of-developer-access/ "MemoMind One Rolls Out New Features and Prepares for a New Stage of Developer Access") [MemoMind One Rolls Out New Features and Prepares for a New Stage of Developer Access](https://thailandbusinessnews.net/press-release/memomind-one-rolls-out-new-features-and-prepares-for-a-new-stage-of-developer-access/ "MemoMind One Rolls Out New Features and Prepares for a New Stage of Developer Access") ##### Subscribe via Email Enter your email address to subscribe and receive notifications of new posts by email. Email Address Subscribe [](https://thailandbusinessnews.net/press-release/dbs-gathers-global-leaders-at-inaugural-asia-future-forward-conference-as-ai-rewrites-the-world/) ## DBS Gathers Global Leaders At Inaugural Asia Future Forward Conference As AI Rewrites The World Shou Chew, Lip-Bu Tan, Hock Tan and Jenny Johnson among influential figures… [](https://thailandbusinessnews.net/press-release/midea-showcases-breakthrough-cooling-technologies-for-high-density-ai-data-centers-at-data-center-world-asia-2026/) ![Midea Showcases Breakthrough Cooling Technologies for High-Density AI Data Centers at Data Center World Asia 2026](https://i0.wp.com/mmx.prnasia.com/media/MS1999346/20260929231123EDT_image_1.jpg?resize=260%2C140&ssl=1 "Midea Showcases Breakthrough Cooling Technologies for High-Density AI Data Centers at Data Center World Asia 2026") ## Midea Showcases Breakthrough Cooling Technologies for High-Density AI Data Centers at Data Center World Asia 2026 SINGAPORE, Oct. 2, 2026 /PRNewswire/ — The Asia Data Centre World 2026… [](https://thailandbusinessnews.net/press-release/registration-opens-for-the-2026-eye-level-math-olympiad/) ![Registration Opens for the 2026 Eye Level Math Olympiad](https://i0.wp.com/mmx.prnasia.com/media/MS2000596/20261001022140EDT_image_1.jpg?resize=260%2C140&ssl=1 "Registration Opens for the 2026 Eye Level Math Olympiad") ## Registration Opens for the 2026 Eye Level Math Olympiad SEOUL, South Korea, Oct. 2, 2026 /PRNewswire/ — Eye Level has opened… [](https://thailandbusinessnews.net/press-release/curaleaf-international-secures-australian-first-with-tga-registered-liquid-medical-cannabis-inhalation-device-and-extends-availability-to-new-zealand/) ![Curaleaf International Secures Australian First with TGA Registered Liquid Medical Cannabis Inhalation Device and Extends Availability to New Zealand](https://i0.wp.com/mmx.prnasia.com/media/MS1612515/Curaleaf-International-Logo.jpg?resize=260%2C140&ssl=1 "Curaleaf International Secures Australian First with TGA Registered Liquid Medical Cannabis Inhalation Device and Extends Availability to New Zealand") ## Curaleaf International Secures Australian First with TGA Registered Liquid Medical Cannabis Inhalation Device and Extends Availability to New Zealand LONDON, Oct. 2, 2026 /PRNewswire/ — Curaleaf International, part of Curaleaf…